La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

SanBio Gestione

Gestione criteri di controllo 2/4

SanBio's Il CEO è Keita Mori, nominato in Feb2013, ha un mandato di 11.5 anni. possiede direttamente 8.74% delle azioni della società, per un valore di ¥ 6.14B. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 2.6 anni e 11.4 anni.

Informazioni chiave

Keita Mori

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	11.6yrs
Proprietà del CEO	8.7%
Durata media del management	2.7yrs
Durata media del Consiglio di amministrazione	11.5yrs

Aggiornamenti recenti sulla gestione

Recent updates

AMMINISTRATORE DELEGATO

Keita Mori (57 yo)

11.6yrs

Mandato

Mr. Keita Mori, MBA, is a Co-Founder of SanBio, Inc., and served as its Chief Executive Officer and served its Co- Chief Executive Officer since 2001 until October 1, 2018. Mr. Mori has been the President...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Toru Kawanishi	Co-Founder & Executive Chairman	11.6yrs	Nessun dato	17.81% ¥ 14.1b
Keita Mori	Co-Founder	11.6yrs	Nessun dato	8.74% ¥ 6.9b
Yoshihiro Kakutani	Corporate Officer of Management Administration	no data	Nessun dato	Nessun dato
Greg Gillas	Senior Vice President of Human Resources & Corporate Services	no data	Nessun dato	Nessun dato
Naoki Tsukahara	Senior Corporate Officer	2.8yrs	Nessun dato	Nessun dato
Kazumi Sawaguchi	Corporate Officer and Head of Japan Regulatory Affairs & Quality Compliance Japan	2.7yrs	Nessun dato	Nessun dato
Keizo Nakada	Corporate Officer & Head of Production	2.2yrs	Nessun dato	Nessun dato
Shinya Hirata	Corporate Officer & Head of Research and Development	2.1yrs	Nessun dato	Nessun dato
Dai Chida	Senior Scientific Advisor	no data	Nessun dato	Nessun dato
Masumi Akahori	In charge of IR	no data	Nessun dato	Nessun dato

2.7yrs

Durata media

Gestione esperta: Il team dirigenziale di 4592 è considerato esperto (durata media dell'incarico 2.6 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Toru Kawanishi	Co-Founder & Executive Chairman	11.6yrs	Nessun dato	17.81% ¥ 14.1b
Keita Mori	Co-Founder	11.6yrs	Nessun dato	8.74% ¥ 6.9b
Noboru Kotani	Independent External Director	11.5yrs	Nessun dato	0.23% ¥ 181.2m
Yoichi Sato	External Auditor	5.2yrs	Nessun dato	Nessun dato
Toshimichi Ueda	External Auditor	11.5yrs	Nessun dato	0.0092% ¥ 7.3m
Masaaki Tanahashi	External Auditor	6.4yrs	Nessun dato	Nessun dato

11.5yrs

Durata media

59.5yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di 4592 è composto da personale esperto e esperto (durata media dell'incarico 11.4 anni).

SanBio Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

SanBio Company Limited, Annual General Meeting, Apr 24, 2024

SanBio Company Limited, Annual General Meeting, Apr 24, 2024

SanBio Co., Ltd. Announces Board Changes

Less than half of directors are independent

Keizo Nakada to Join Sanbio as Corporate Officer and Head of Production

SanBio Company Limited Appoints Andrew Liu as Chief Strategy Officer

Recent updates

New major risk - Revenue and earnings growth

Sanbio Co., Ltd. Obtains Marketing Approval for AKUUGO Suspension for Intracranial Implantation

SanBio Company Limited to Report Q2, 2025 Results on Sep 17, 2024

Price target increased by 20% to JP¥960

Price target increased by 23% to JP¥983

New major risk - Revenue and earnings growth

SanBio Company Limited Announces Update on Status of Manufacturing and Marketing Approval for Sb623 Chronic Traumatic Brain Injury Program in Japan

SanBio Company Limited to Report Q1, 2025 Results on Jun 13, 2024

New major risk - Revenue and earnings growth

Price target decreased by 30% to JP¥1,214

SanBio Company Limited, Annual General Meeting, Apr 24, 2024

SanBio Company Limited, Annual General Meeting, Apr 24, 2024

Price target increased by 18% to JP¥2,100

Forecast to breakeven in 2027

SanBio Company Limited to Report Fiscal Year 2024 Results on Mar 18, 2024

Sanbio Co., Ltd. Provides Update on Status of Manufacturing and Marketing Approval for Sb623 Chronic Traumatic Brain Injury Program in Japan

New major risk - Financial position

SanBio Company Limited Provides Update on Status of Manufacturing and Marketing Approval for SB623 Chronic Traumatic Brain Injury (TBI) Program in Japan

SanBio Company Limited to Report Q3, 2024 Results on Dec 14, 2023

SanBio Company Limited to Report Q2, 2024 Results on Sep 15, 2023

Consensus revenue estimates fall by 15%

SanBio Co., Ltd. Updates on Status of Manufacturing and Marketing Approval for SB623 Chronic Traumatic Brain Injury Program in Japan

Price target increased by 13% to JP¥2,290

No longer forecast to breakeven

SanBio Company Limited to Report Q1, 2024 Results on Jun 14, 2023

Price target increased by 12% to JP¥2,465

No longer forecast to breakeven

Price target increased by 12% to JP¥2,465

SanBio Company Limited to Report Fiscal Year 2023 Results on Mar 16, 2023

Forecast to breakeven in 2026

SanBio Co., Ltd. Announces Board Changes

SanBio Company Limited Provides Earnings Guidance for the Fiscal Year Ending January 31, 2023

Less than half of directors are independent

SanBio Company Limited to Report Q3, 2023 Results on Dec 15, 2022

Sanbio Company Limited Provides Earnings Guidance for the Fiscal Year Ending January 31, 2023

Price target decreased to JP¥2,233

SanBio Company Announces Update on Status of Manufacturing and Marketing Approval for SB623 Chronic Traumatic Brain Injury (TBI) Program in Japan

Keizo Nakada to Join Sanbio as Corporate Officer and Head of Production

Price target decreased to JP¥2,200

SanBio Company Limited Provides Consolidated Earnings Guidance for the First Half and Full Year Ending January 31, 2023

SanBio Company Limited Appoints Andrew Liu as Chief Strategy Officer

Less than half of directors are independent

Sanbio Group Provides an Update on One-Year Analysis of the Phase 2 STEMTRA Trial

Sanbio Company Limited Announces Filing with Japan’S Ministry of Health, Labour, and Welfare for Manufacture and Marketing Approval as A Regenerative Medicine Product for the Investigational Product Sb623

Price target increased to JP¥2,900

SanBio Company Limited announced that it expects to receive ¥33.75 million in funding from Nomura Securities Co., Ltd.

SanBio Company Limited Provides Consolidated Earnings Guidance for the Fiscal Year Ending January 31, 2022

SanBio Company Limited Provides Consolidated Earnings Guidance for the Fiscal Year Ending January 31, 2022

Corporate Officer & Business Head of Japan/Asia Hiroshi Yamamoto has left the company

Price target increased to JP¥2,660

SanBio Company Limited Provides Consolidated Earnings Guidance for the First Half and Full Year of the Fiscal Year Ending January 31, 2022

SanBio Company Limited Provides Earnings Guidance for the First Half and Full Year of the Fiscal Year Ending January 31, 2022

Sanbio Company Limited Presents STEMTRA Phase 2 Trial Results At the 44Th Annual Meeting of the Japan Society of Neurotraumatology

SanBio Company Limited to Report Fiscal Year 2021 Results on Mar 17, 2021

SanBio Company Limited Announces Publication of STEMTRA Phase 2 Interim Analysis for SB623 in Neurology

Price target lowered to JP¥2,683

New 90-day low: JP¥1,388

Price target lowered to JP¥2,683

SanBio Company Limited to Report Q3, 2021 Results on Dec 15, 2020

Tokio Marine & Nichido Fire Insurance Co., Ltd. agreed to acquire 9.74% stake in CareNet, Inc. (TSE:2150) from SanBio Company Limited (TSE:4592).

SanBio Company Limited Appoints Hiroyasu Narita as Head of Clinical Development, Effective from October 1, 2020

SanBio Company Limited to Report Q2, 2021 Results on Sep 14, 2020

AMMINISTRATORE DELEGATO

Mandato

Gruppo dirigente

Durata media

Membri del Consiglio di amministrazione

Durata media

Età media